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DifferentiationExtracellular ATP is a danger signal released by dying and damaged cells, and it functions as an
immunostimulatory signal that promotes inﬂammation. However, extracellular adenosine acts as
an immunoregulatory signal that modulates the function of several cellular components of the
adaptive and innate immune response. Consequently, the balance between ATP and adenosine con-
centration is crucial in immune homeostasis. CD39 and CD73 are two ectonucleotidases that coop-
erate in the generation of extracellular adenosine through ATP hydrolysis, thus tilting the balance
towards immunosuppressive microenvironments. Extracellular adenosine can prevent activation,
proliferation, cytokine production and cytotoxicity in T cells through the stimulation of the A2A
receptor; however, recent evidence has shown that adenosine may also affect other processes in
T-cell biology. In this review, we discuss evidence that supports a role of CD73 and CD39 ectonu-
cleotidases in controlling naive T-cell homeostasis and memory cell survival through adenosine pro-
duction. Finally, we propose a novel hypothesis of a possible role of these ectonucleotidases and
autocrine adenosine signaling in controlling T-cell differentiation.
 2015 The Authors. Published by Elsevier B.V. on behalf of the Federation of European Biochemical
Societies. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/
licenses/by-nc-nd/4.0/).1. Introduction In healthy tissues, ATP is almost exclusively present inside thePurinergic mediators, such ATP and adenosine, can be released
into the extracellular space and act as positive or negative signals
inﬂuencing the outcome of immune responses. Whereas intracel-
lular ATP is primarily used to drive energy-requiring processes,
such as active transport, cell motility and biosynthesis, extracellu-
lar ATP is considered a powerful signaling molecule [1]. ATP that is
released from damaged or stressed cells acts as a ‘‘ﬁnd-me’’ signal
that guides phagocytes to inﬂammatory sites, promoting the clear-
ance of damaged cells [2]. ATP also induces pro-inﬂammatory
responses, such as inﬂammasome activation and the subsequent
release of inﬂammatory cytokines [3]. In contrast, extracellular
adenosine accumulation serves as ‘‘reporter’’ of excessive tissue
damage. It has been shown that adenosine acts on diverse immune
cells, mediating mainly anti-inﬂammatory effects by inhibiting
activated immune cells in a negative feedback loop to prevent
additional tissue damage [4].cells, reaching millimolar concentrations, whereas extracellular
ATP concentration is in the low nanomolar concentrations [5]. A
study using a bioassay approach to measure ATP concentrations
in several tissues, has demonstrated that ATP is in the hundreds
micromolar range in the tumor intersticium [6]. In addition to its
release during tissue damage, ATP may be released by immune
cells upon activation. It has been reported that T cells and neu-
trophils release ATP through pannexin 1 channels [7,8] whereas
B cells release ATP stored in calcium sensitive vesicles. Once in
the extracellular environment, ATP is hydrolyzed by plasma mem-
brane nucleotidases to generate ADP, AMP and ﬁnally adenosine
[9]. Evidence of adenosine bioavailability has been demonstrated
by the fact that A2A receptors are readily activated in CD8+ and
CD4+ T cells, since A2A receptor deﬁciency on T cells affects their
numbers in the periphery [10] and effector-memory differentiation
in all T cells [11]. This demonstrates that at least the extracellular
levels of adenosine detected by T cells under homeostatic condi-
tions are enough to signal through A2A receptors.
The extracellular concentration of adenosine depends on: (i) the
balance between its release from cells, (ii) its re-uptake by the
bi-directional adenosine transport processes, and (iii) its
Fig. 1. Expression of CD39 and CD73 ectonucleotidases during CD8 T cell differentiation. Naive T cells (TNAIVE) express CD73 ectonucleotidase which is rapidly downregulated
upon activation and differentiation into effector T cells (TEFF). Conversely, CD39 expression is upregulated upon T cell activation. Central memory (TCM) and effector memory
(TEM) T cells express both, CD73 and CD39 ectonucleotidases.
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(NTPDase-1) and CD73 (ecto-50-nucleotidase) are two cell-surface
ecto-enzymes that dephosphorylate ATP into its metabolites,
ADP, AMP and adenosine, in a tightly regulated process [13]. The
conversion of ATP into AMP is catalyzed by CD39, [14],
whereas CD73, a glycosyl phosphatidylinositol (GPI)-linked
membrane-bound glycoprotein, catalyzes the dephosphorylation
of AMP into adenosine [15]. Whereas the conversion of ATP to
AMP by CD39 can be reversed by the actions of the extracellular
diphosphate kinases NDP kinase and adenylate kinase, the conver-
sion of AMP into adenosine by CD73 is reversible only following
intracellular transport of adenosine, where it can be converted to
AMP by adenosine kinase [16].
CD39 and CD73 have been widely considered pivotal in the gen-
eration of immunosuppressive microenvironments through adeno-
sine production [13,17]. In accordance with this idea, CD39 and
CD73 ectonucleotidases are reported as active players in several
diseases, such as cancer, autoimmunity, allergy, and ischemia–
reperfusion injury (reviewed in [17]). In this review, we explore
recent evidence showing that, besides its immunosuppressive role,
CD39 and CD73 ectonucleotidases may also be involved in the reg-
ulation of other aspects of T-cell biology, such as naive cell home-
ostatic survival, memory cell survival and differentiation.
2. CD39 and CD73 expression in immune cells
CD39 and CD73 are expressed at different levels in a variety of
tissues, including the heart, placenta, lung, liver, colon, brain and
kidney [18–20]. Additionally, these ectonucleotidases are highly
upregulated in a large number of tumors, such as melanoma, leu-
kemia, pancreatic, liver, gastric, colon and breast cancer [13,21].
Interestingly, CD39 and CD73 ectonucleotidases are also expressed
by immune cells, including monocytes, neutrophils, dendritic cells,
myeloid-derived suppressor cells, B lymphocytes, and some T-cell
subsets [22–27].
2.1. T-cell subsets expressing CD39 and CD73 ectonucleotidases
CD39 and CD73 ectonucleotidases are highly expressed in mur-
ine CD4+ Foxp3+ regulatory T cells (Treg cells) and have been
extensively used as markers of this T-cell subpopulation [23,28].
Human Treg cells have been reported to express CD39 on their sur-
face, but in contrast to murine Treg cells, CD73 is predominantly
intracellularly expressed. It has been demonstrated that CD39and CD73 ectonucleotidases are key in adenosine production by
Treg cells and therefore are considered to be part of their immuno-
suppressive arsenal [23].
Some reports have shown that in addition to Treg cells, other
T-cell subsets express the CD39 and CD73 ectonucleotidases.
Thpp cells are primed CD4+ T cells that remain as proliferating
but uncommitted precursor cells. These cells express high levels
of CD44, secrete IL-2 and can subsequently differentiate into Th1
and Th2 cells in appropriate cytokine environments [29]. It has
been described that these cells express CD73 [30] and are able to
produce adenosine and suppress the proliferation of CD4+ or
CD8+ T cells in in the presence of exogenous AMP [28].
Ghiringhelli and collaborators have demonstrated that Th17
cells generated with TGF-b and IL-6 express both ectonucleoti-
dases. Moreover, they suggest that Th17 cells are able to produce
adenosine and limit IFN-c and granzyme B production by CD4+
and CD8+ T cells, thus exhibiting protumoral activity [31].
However, these results must be interpreted with some caution,
since the reduction in IFN-c production by CD4+ T cells was
observed only at high Th17:Teff ratios (1:1 ratio). Moreover, sev-
eral studies have demonstrated that Th17 cells present antitumor
activity [32–37] even when ectonucleotidase expression by Th17
cells has been demonstrated [38]. Interestingly, we have observed
that other T helper subsets, such as Th1 cells, also express both
ectonucleotidases in vivo (unpublished data), suggesting that in
addition to Treg cells, other T helper subsets may also be able to
produce adenosine. Thus, it is tempting to speculate that CD39
and CD73 ectonucleotidases in T helper subsets may be required
for other processes in addition to promoting immunosuppressive
microenvironments through adenosine production.
Two reports have shown that a subset of human and murine
memory CD4+ T cells express CD39 [39,40]. Although these
CD39+ memory T cells have ATPase activity, they do not possess
immunosuppressive activity. In consequence, it has been sug-
gested that CD39 expression by memory T cells may instead con-
tribute to dampening ongoing inﬂammatory processes and/or
rescue these cells from ATP-induced apoptosis/necrosis [40]. In
agreement with previous evidence from the literature [15,41], we
found that naïve CD8+ T cells express CD73 and downregulate its
expression upon activation (unpublished results). Although cur-
rently there is no evidence of a role of CD73 in CD8+ T cell differ-
entiation, these results suggest that CD73 downregulation may be
necessary to prevent autocrine adenosine signaling during T-cell
activation, thus allowing the transition to effector cells (Fig. 1).
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In addition to T cells, evidence from the literature demonstrates
that neutrophils and B cells also express CD39 and/or CD73
ectonucleotidases. It has been reported that extracellular ATP and
adenosine both play critical roles in the polarization and migration
of neutrophils via tightly coordinated processes that involve the
activation of P2Y2 and A3 receptors [7]. The group of Junger has
further demonstrated that CD39 localizes at the leading edge
where most of the ATP released by neutrophils accumulates. This
suggests a dual role for CD39 in the rapid decrease of ATP concen-
trations at the leading edge and in the initiation of adenosine for-
mation, which contributes to directed migration of neutrophils
[42]. Moreover, a recent report has shown that ATP is stored in
secretory vesicles in human B cells and that may be released upon
B cell receptor stimulation. This ATP may be hydrolyzed to adeno-
sine by the tandem action of CD39 and CD73 ectonucleotidases
expressed by B cells, inducing an autocrine adenosine signaling
which is necessary for class switch recombination. In agreement
with this evidence, patients with impaired class switching anti-
body responses present B cells lacking CD73 expression [43]. All
these data provide evidence of the involvement of CD39 and
CD73 ectonucleotidases in adenosine production and in initiating
an autocrine adenosine signaling in immune cells.
2.3. Factors that induce CD39 and CD73 expression
It has been described that ectonucleotidases expression is regu-
lated by several transcription factors, including Sp1 [44], Stat3 and
Gﬁ-1 [31]. CD39 and CD73 expression and function are upregu-
lated under hypoxic conditions [45] as well by the presence of
TGF-b1 and IL-6 [31,46], type 1 IFNs [47] and Wnt signaling path-
way agonists [48]. In contrast, inﬂammatory cytokines, such as
IL-4, IL-12, IL-21 and IFN-c, can prevent CD73 expression induced
by TGF-b1 [46].
3. Adenosine and immunosuppression
Adenosine has been mainly related to immunosuppression dur-
ing the anti-tumor immune response. In this section, we gather all
of the evidence demonstrating a role of this nucleoside in sup-
pressing T-cell responses and promoting tumor immune evasion.
3.1. Adenosine as an immunosuppressive molecule for T cells
Adenosine signaling is mediated by four G-protein-coupled ade-
nosine receptors: A1, A2A, A2B and A3. The A1 and A3 adenosine
receptors are coupled to the Gi/o subunit and their stimulation
leads to the inhibition of adenylyl cyclases, decreasing intracellular
cyclic AMP (cAMP) levels. On the other hand, A2A and A2B adeno-
sine receptors are coupled to the Gs subunit, which stimulates
cAMP production and PKA activation [49,50]. Stimulation of A2A
and A2B receptors by adenosine has been reported to mediate sup-
pressive effects on T cells, dendritic cells, neutrophils, macro-
phages and other immune cells [51]. The A2A receptor is the
predominant subtype found on T cells and is induced upon T-cell
activation [17].
A2A receptor stimulation and the subsequent activation of PKA
lead to cAMP responsive element-binding protein (CREB) phospho-
rylation, which can bind to the p65 subunit of the NF-kB transcrip-
tion complex inhibiting NF-kB-driven gene expression [52].
Additionally, there is evidence that indicates that PKA directly inhi-
bits the Ras/MAP kinase pathway [53], which is involved in T-cell
proliferation [54]. Accordingly, it has been described that
extracellular adenosine prevents the activation, proliferation andexpansion of T cells [23,55] and may also inhibit cytotoxicity and
cytokine production [56]. Moreover, A2A receptor stimulation
inhibits Th1 and Th2 cell differentiation by decreasing naive
T-cell proliferation and IL-2 production [57]. Stimulation of
the A2A receptor has also been shown to promote the generation
of Foxp3+ and LAG-3+ Treg cells and reduce Th17 cell differentia-
tion by increasing TGF-b and decreasing IL-6 production by
splenocytes [58].
3.2. Adenosine production by regulatory T cells
Treg cells are responsible for inducing and maintaining periph-
eral tolerance [59]. One of the suppressive mechanisms attributed
to Treg cells is metabolic disruption, ascribed in part to the expres-
sion of CD39 and CD73 ectonucleotidases and the concomitant ade-
nosine production [23,28,60]. The contribution of CD39 in
immunoregulation by Treg cells is supported by the occurrence of
alopecia areata and experimental autoimmune encephalomyelitis
in CD39-deﬁcient mice and by the failure of CD39 Treg cells to
suppress contact hypersensitivity [61]. The inhibitory effect of ade-
nosine on effector T cells is mediated by the blockade of T-cell
receptor signaling due to an increase in cAMP after A2A receptor
stimulation [62,63]. In addition to its role in the generation of ade-
nosine and the creation of an immunosuppressive microenviron-
ment, CD39 expression has also been related to the ability of Treg
cells to survive in ATP-rich sites, such as in inﬂamed tissue [60].
Interestingly, Sitkovski and collaborators recently presented
evidence of a positive autocrine feedback loop via A2A adenosine
receptors on Treg cells. This group demonstrated that T-cell activa-
tion in the presence of an A2AR agonist resulted in the expansion
of Treg cells and the generation of Treg cells with stronger
immunoregulatory activity [64].
3.3. Adenosine as a mechanism of immune escape in cancer
It has been reported that there is an important increase in CD39
and CD73 expression in blood neoplasias, such as leukemia and
lymphoma, as well as in several solid tumors [21]. Thus, adenosine
generation in the tumor microenvironment has been proposed to
be one of the mechanisms used by tumors to create an immuno-
suppressive microenvironment and avoid tumor destruction.
Adenosine-related tumor immune escape is mediated by several
mechanisms: (i) the inhibition of activation, expansion and cyto-
kine production by T cells [56,65,66], (ii) the impairment of
T-cell and NK-cell cytotoxic activity [56,67], (iii) the induction of
Treg cells and MDSCs [26,58], (iv) the inhibition of the maturation
and activation of dendritic cells [68], and (v) the promotion of M2
conversion in tumor-associated macrophages [69], among many
others.
In addition to its effect on immune populations, it has been
reported that adenosine may also regulate intrinsic functions of
tumor cells, such as proliferation, apoptosis, angiogenesis and
metastasis (reviewed in [70]).
4. Other ectonucleotidase functions
In addition to their role in adenosine production, CD39 and
CD73 are involved in other processes, such as ATP clearance,
co-stimulation and cell adhesion. These aspects will be discussed
in the following section.
4.1. CD39 and ATP clearance
Extracellular ATP can be sensed by purinergic P2 receptors.
These receptors include cation-selective receptor channels (P2X)
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receptors are expressed in immune and epithelial cells where ATP
sensing induces mainly pro-inﬂammatory responses [71]. It has
been demonstrated that high doses of ATP induce necrotic lysis
through P2X7 receptor signaling in T cells [72]. Thus, cells provided
with a mechanism to deplete ATP, such as CD39-mediated hydrol-
ysis of ATP, may be more ﬁt compared with cells lacking CD39
expression when entering ATP-rich sites.
The ﬁrst evidence in support of this hypothesis came from the
observation that CD39 expression on Treg cells is required not only
to exert their regulatory function but also to proliferate. Regulatory
T cells are highly sensitive to ATP-induced necrotic lysis through
purinergic receptor P2X7 signaling [72]. Importantly, inhibition
of CD39 catalytic activity has been shown to reduce the prolifera-
tive capacity of Treg cells in the presence of extracellular ATP [60].
Thus, it has been proposed that CD39 expression by Treg cells not
only mediates immunosuppression through the production of ade-
nosine but is also required to lower extracellular ATP concentra-
tion below the toxic threshold [60].
We and others [46] have demonstrated that CD39 expression is
upregulated in activated CD4+ T cells. Moreover, we observed that,
in addition to Treg cells, other effector T helper subsets, such as
Th1 and Th17 cells, also express CD39, and its expression is upreg-
ulated following the inﬁltration of ATP-rich sites, such as the tumor
microenvironment (unpublished results).
In line with all the evidence pointing to a role of CD39 ectonu-
cleotidase in depleting ATP, our unpublished data shows that
in vitro-generated Th17 cells that express higher levels of CD39
expression are less susceptible than CD39- Th17 cells to
ATP-induced necrotic lysis. Moreover, when transferred into
tumor-bearing mice, CD39- Th17 cells rapidly convert to CD39+
cells within the tumor microenvironment. Although all of this evi-
dence does not rule out a role of CD39 in the generation of adeno-
sine and immunosuppressive microenvironments, it suggests that
this ectonucleotidase is upregulated in effector T-cell populations
and provides a mechanism of survival in ATP-rich sites.
4.2. CD73 as a co-stimulatory molecule
It has been proposed that, besides its enzymatic activity, CD73
may function as a co-stimulatory molecule for T cells.
Cross-linking CD73 with monoclonal antibodies (mAb) in the pres-
ence of PMA or in combination with submitogenic concentration of
anti-CD3 mAb stimulates human peripheral blood T cells to prolif-
erate, express CD25 and secrete IL-2 [73,74], suggesting that CD73
could trigger an activation signal similar to other GPI-anchored
lymphocytes antigens, such as Thy-1 and Ly-6 [75]. Other studies
revealed that naïve CD45RAhi CD45ROlo CD8+ T cells, which
express CD73, have low responsiveness to activation through
immobilized anti-CD3, which can be overcome when CD3 and
CD73 are simultaneously cross-linked by immobilized anti-CD73
and anti-CD3 mAb [76]. This suggests that CD73 could reduce
the threshold for activation of naïve T cells when they ﬁrst encoun-
ter antigen [77].
4.3. CD73 in cell adhesion
The addition of anti-CD73 mAb to in vitro cultured endothelial
cells can inhibit the binding of lymphocytes, suggesting that CD73
expression by endothelial cells may mediate the binding of lym-
phocytes to the endothelium [78]. In the same line, CD73 expres-
sion on follicular dendritic cells mediates the adhesion between
B cells and follicular dendritic cells in vitro, which can be inhibited
by the presence of an anti-CD73 mAb [22]. On T lymphocytes, the
engagement of CD73 by an anti-CD73 mAb increases their binding
to cultured endothelial cells in an LFA-1-dependent fashion,suggesting that CD73 may control the activation step in the multi-
step cascade of lymphocyte extravasation [79].
5. CD73 and adenosine in the control of T-cell differentiation
Upon activation, naive T cells give rise to a heterogeneous pro-
geny of short-lived effector cells (SLEC) and memory precursor
cells (MPEC) that provide acute and long-term protection respec-
tively. The formation of memory T cells is an important feature
of adaptive immunity and rely at least in part on the ability of T
cells to survive and/or self-renew in an antigen-independent man-
ner [80]. In the following section, we will discuss recent evidence
regarding the role of CD73 and adenosine in the maintenance of
naive and memory T cell phenotype, including naive T cell home-
ostatic survival, memory T cell survival, and stemness of
memory-like T cells. We will discuss recent studies supporting
the idea that CD73-mediated adenosine signaling can restrain T
cell effector differentiation favoring the formation of long-lived
memory T cells.5.1. Akt inhibition and arrest of CD8 T-cell differentiation
It has been proposed that the magnitude of TCR, costimulation
and cytokine signaling are responsible of ﬁne-tuning CD8+ T cell
fate. While strong T cell stimulation promotes the differentiation
of short-lived effector T cells (SLEC), weak T cell stimulation
induces a memory phenotype which is characterized by
long-term survival capacity [81]. Importantly, several inputs that
control this fate decision converge at the activation of Akt pathway
[82]. Accordingly, recent studies have highlighted the role of the
Akt pathway as a central node in memory versus effector differen-
tiation of CD8+ T cells (reviewed in [82]). Thus, Akt signaling has
been shown to control several transcriptional regulators of T cell
differentiation such as FOXO, mTOR and the Wnt/b-catenin axis
(Fig. 2). Interestingly, A2A receptor stimulation decreases
TCR-mediated activation of the Akt pathway, supporting a role of
extracellular adenosine in modulating T cell activation signaling
[10,83].
All of this evidence sustains the hypothesis that adenosine sig-
naling through A2A receptors may restrain T-cell differentiation by
reducing Akt activation (Fig. 2). In agreement with this idea, Akt
inhibition has shown to enhance the formation of long-lived mem-
ory CD8+ T cells [84,85]. Furthermore, Akt pharmacological inhibi-
tion during ex-vivo expansion of tumor inﬁltrating CD8+ T cells
promotes a phenotypic (CD62Lhi), transcriptional (Tcf7, Lef1,
Foxo, Klf2, and Sell) and metabolic proﬁle (increased fatty acid oxi-
dation) characteristic of long-lived memory CD8+ T cells. All of
these features were associated with enhanced T-cell persistence
upon adoptive transfer and tumor regression following adoptive
T-cell therapy [84]. Conversely, it has been demonstrated that sus-
tained Akt activation enhances effector functions, drives differenti-
ation into terminal effector cells and reduces the potential of CD8+
T cells to survive and differentiate into memory cells [86,87].
5.2. Inhibition of CD127 down-regulation and memory T-cell survival
In contrast to all of the evidence pointing to a role of adenosine
in generating immunosuppressive microenvironments that favor
tumor progression [65,66], Linden and collaborators demonstrated
that global deletion of A2A receptors impairs memory CD8+ T-cell
accumulation in tumors and promotes tumor progression. These
results were recapitulated in Adora2aﬂ/ﬂ Lck-Cre+/ mice, which
lack A2A receptors, speciﬁcally in T cells [88]. Additionally, deﬁ-
ciency in the A2A receptor in CD8 T cells led to impaired survival
upon adoptive transfer into tumor-bearing mice, which correlated
Fig. 2. The Akt pathway as a central node in CD8+ T-cell memory versus effector differentiation. Signals through the TCR, co-stimulatory molecules and cytokine receptors
converge to activate the Akt pathway. The magnitude of Akt activation ﬁne-tunes T-cell differentiation. Akt can inhibit the activity of memory-promoting transcription
factors, such as FOXO and TCF/LEF/b-catenin. On the other hand, Akt activates mTORC1, which in turn promotes T-cell differentiation by facilitating anabolic metabolism and
promoting the expression of T-bet. Thus, Akt activation drives CD8+ T cells to terminal differentiation at the expense of memory formation. A2A receptor stimulation drives
cAMP accumulation followed by PKA activation. PKA is a negative regulator of Akt, thus extracellular adenosine may regulate T cell differentiation by preventing Akt
activation.
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demonstrate a T-cell intrinsic mechanism involving an A2A
receptor-dependent control of CD127 expression in the survival
of long-lived memory CD8+ T cells.
Remarkably, the above-mentioned results demonstrate that
adenosine signaling is active in memory CD8+ T cells and functions
to maintain CD127 expression and T-cell survival. However, is not
clear yet how adenosine availability is controlled in these scenar-
ios. CD8+ T cells express CD39 and CD73 ectonucleotidases
[39,89,90], supporting the hypothesis that adenosine may be gen-
erated by T cells themselves through CD39 and CD73-mediated
extracellular ATP hydrolysis. Thus, ectonucleotidase expression
by T cells may support an autocrine adenosine signaling that is
necessary for CD127 expression and survival of memory CD8+ T
cells. In support of this idea, we have shown that memory and
naive CD8+ T cells, but not effector T cells, express high levels of
CD73 which is responsible for generating extracellular adenosine
(unpublished data, Fig. 1). Moreover, tumor inﬁltrating CD8+ T
cells that lack CD73 expression, express markers of SLECs, such
as KLRG1, and downregulate markers that are associated with
long-lived memory T cells, such as CD127 and CD62L (unpublished
data). Because CD73 is able to generate adenosine by the hydroly-
sis of AMP, these data suggest that CD73-driven adenosine produc-
tion mediates an autocrine loop that arrests T-cell differentiation,
thus favoring the maintenance of long-lived memory T cells.
5.3. Inhibition of CD127 down-regulation and homeostatic naive T-cell
survival
New evidence supports the hypothesis that adenosine may reg-
ulate CD8+ and CD4+ naive T-cell homeostatic survival and periph-
eral maintenance. A recent report has demonstrated that
adenosine favors naive CD8+ and CD4+ T-cell homeostatic survivalby preventing CD127 downregulation following T-cell receptor
stimulation by low afﬁnity self-peptide-MHC complexes. This
effect is mediated by adenosine-induced activation of PKA,
followed by the reduction of the TCR-mediated activation of the
Akt pathway. The downregulation of CD127 correlates with less
persistence in vivo, due to decreased anti-apoptotic Bcl-2 expres-
sion, which is a downstream target of IL-7 signaling [10].
6. Concluding remarks
Extracellular ATP and adenosine are considered to be impor-
tant factors in regulating immune responses. Whereas ATP acts
as a danger signal that promotes inﬂammation, extracellular ade-
nosine acts as an immunoregulatory signal that modulates adap-
tive and innate immune response functions. As a consequence,
the ATP/adenosine balance is crucial in immune homeostasis.
CD39 and CD73 are two ectonucleotidases that cooperate in the
generation of extracellular adenosine through ATP hydrolysis.
These ectonucleotidases may be considered to be ‘‘immunological
switches’’, tilting the balance from inﬂammation to immunosup-
pression. Although the role of adenosine in inducing immunosup-
pression is well established, recent evidence has shown that this
nucleoside may also affect other T-cell biology processes, such
as T-cell homeostasis, memory survival and differentiation.
CD39 and CD73 expression is ﬁnely regulated during the transi-
tion of naive/memory T cells to effector cells. Thus, through
ectonucleotidase expression, naive/memory T cells are endowed
with the ability to produce adenosine and lose this ability as they
transition to more differentiated cells. We propose that ectonu-
cleotidases that are expressed by naive/memory T cells allow ade-
nosine production, which signals in an autocrine manner,
resulting in the arrest of T-cell differentiation in the absence of
strong TCR signaling.
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